Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Ora, Inc.

    Client Virtual Booth

    ORA, INC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Ora, Inc
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    300 Brickstone Square Andover, Massachusetts 01810
    Telephone
    Telephone
    (978) 685-8900
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.oraclinical.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ora-inc/
    Twitter
    Twitter
    https://twitter.com/oraclinical

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Stuart Therapeutics Announces First Patient, First Visit in Its Phase 3 Clinical Trial of Vezocolmitide for Dry Eye Disease

    Details:

    ST-100 (vezocolmitide) is part of Stuart's PolyCol™ (PolyCol) platform of synthesized collagen mimetics, which target and treat disease damaged extracellular matrix (ECM) collagen. It is under phase 3 clinical development for the treatment of Dry Eye Disease.


    Lead Product(s): Vezocolmitide

    Therapeutic Area: Ophthalmology Product Name: ST-100

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Recipient: Stuart Therapeutics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 29, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Okuvision's Low-Concentration Atropine OT-101 has been Approved by the US FDA to Carry out The Pediatric Research Program (IPSP)

    Details:

    OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.


    Lead Product(s): Atropine Sulfate

    Therapeutic Area: Ophthalmology Product Name: OT-101

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Recipient: OcuMension Therapeutics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 22, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Okvision Low Concentration Atropine Sulfate Eye Drops OT-101 Completed the First Subject Enrollment and Plans to Carry out Real-World Research

    Details:

    OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.


    Lead Product(s): Atropine Sulfate

    Therapeutic Area: Ophthalmology Product Name: OT-101

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Recipient: OcuMension Therapeutics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 07, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Okuvision Low Concentration Atropine Sulfate Eye Drops Ot-101 was Approved by the US FDA For Phase III Clinical Trials

    Details:

    OT-101 (atropine sulfate eye drops) inhibits the muscarinic actions of acetylcholine, which is investigated for dry eye syndrome and Myopia Progressive.


    Lead Product(s): Atropine Sulfate

    Therapeutic Area: Ophthalmology Product Name: OT-101

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Recipient: OcuMension Therapeutics

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 22, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    famar-2024-07-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search